Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo-controlled, clinical trial
2024

Caffeine Supplement and Liver Health in Cirrhotic Patients

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): Seyed Ali Abbas-Hashemi, Zahra Yari, Behzad Hatami, Amir Anushiravani, Shadi Kolahdoozan, Ali Zamanian, Nadia Akbarzadeh, Azita Hekmatdoost

Primary Institution: Shahid Beheshti University of Medical Sciences, Tehran, Iran

Hypothesis

Can caffeine supplementation improve inflammation and liver function in cirrhotic patients?

Conclusion

Daily supplementation of 400 mg caffeine in cirrhotic patients can significantly improve liver fibrosis and reduce inflammatory factors.

Supporting Evidence

  • Caffeine supplementation resulted in a significant reduction in inflammatory biomarkers compared to placebo.
  • A significant improvement in liver indices including AST to platelet ratio index (APRI) was observed after 8 weeks of caffeine supplementation.
  • The compliance of participants was over 85% with no adverse events reported.

Takeaway

Giving cirrhotic patients caffeine can help their liver feel better and reduce inflammation.

Methodology

This was a randomized, double-blind, placebo-controlled trial with 50 cirrhotic patients receiving either caffeine or placebo for eight weeks.

Potential Biases

None reported.

Limitations

The study had a small sample size and short duration.

Participant Demographics

Patients aged 18-75 with cirrhosis induced by viral hepatitis, fatty liver disease, or autoimmune hepatitis.

Statistical Information

P-Value

P<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.heliyon.2024.e41138

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication